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Diabetes mellitus (DM) and osteoporosis (OP) are common disorders with a significant
health burden, and an increase in fracture risk has been described both in type 1 (T1DM)
and in type 2 (T2DM) diabetes. The pathogenic mechanisms of impaired skeletal strength
in diabetes remain to be clarified in details and they are only in part reflected by a variation
in bone mineral density. In T2DM, the occurrence of low bone turnover together with a
decreased osteoblast activity and compromised bone quality has been shown. Of note,
some antidiabetic drugs (e.g., thiazolidinediones, insulin) may deeply affect bone metabo-
lism. In addition, the recently introduced class of incretin-based drugs (i.e., GLP-1 receptor
agonists and DPP-4 inhibitors) is expected to exert potentially beneficial effects on bone
health, possibly due to a bone anabolic activity of GLP-1, that can be either direct or indirect
through the involvement of thyroid C cells. Here we will review the established as well as
the putative effects of incretin hormones and of incretin-based drugs on bone metabolism,
both in preclinical models and in man, taking into account that such therapeutic strategy
may be effective not only to achieve a good glycemic control, but also to improve bone
health in diabetic patients.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is characterized by insulin resis-
tance and by a progressive functional loss of pancreatic beta cells.
Islet dysfunction is characterized by failure of beta cells to compen-
sate for insulin resistance and by a concomitant enhanced glucagon
release from alpha cells. Of note, an alteration of insulin/glucagon
balance seems to be one of the key factors in disease physiopathol-
ogy (Butler et al., 2003; Giorgino et al., 2005; Marchetti et al.,
2008). An appropriate strategic approach for T2DM treatment
should therefore target insulin resistance, beta-cell dysfunction,
and increased glucagon levels.
The role of incretin hormones (e.g., GLP-1, glucagon like pep-
tide 1; GIP, glucose-dependent insulinotropic peptide) in T2DM
therapy has recently received much attention, because of the ben-
eficial actions of these molecules on the pancreatic islet (Ahren,
2003; Marchetti et al., 2012). Incretin-based therapy encompasses
two classes of drugs: GLP-1 receptor agonists and dipeptidyl
peptidase-4 (DPP-4) inhibitors. Of note, in the light of physio-
logical actions of incretin hormones, such drugs are expected to
exert potentially beneficial effects beyond glycemia, including on
bone health, possibly due to a bone anabolic activity of GLP-1
that can be either direct or indirect, through the involvement of
thyroid C cells. This is of potential interest, in the light that an
increase in fracture risk has been described both in type 1 diabetes
(T1DM) and in T2DM (Hamann et al., 2012). The pathogenic
mechanisms of impaired skeletal strength in diabetes remain to be
clarified in detail, and they are only in part reflected by a variation
in bone mineral density (BMD). In T2DM, the occurrence of low
bone turnover has been shown together with decreased osteoblast
activity and compromised bone quality. Of note, some antidia-
betic drugs (e.g., thiazolidinediones, insulin) may have important
effects on bone metabolism.
Here we review the established as well as the putative effects
of incretin-based drugs on bone metabolism, both in preclinical
models and in man, taking into account that such therapeutic
strategy may be effective not only to achieve a good glycemic
control, but also to improve bone health in diabetic patients.
A literature search was performed screening PubMed database
using combinations of the following search terms: “DM”; “type
1 diabetes”; “type 2 diabetes”; “bone metabolism”; “incretin hor-
mones”; “GLP-1”; “incretin-based therapy”; “DPP-4 inhibitors.”
This initial screening identified a total of 2492 records. We
then included only publications published in English, removed
duplicates, and took into final consideration those articles
directly examining the relationship between incretin hormones or
incretin-based therapies with bone metabolism and bone turnover
markers in diabetic patients, in experimental animal models and
in cell lines. Overall, 110 publications were included in our review.
INCRETIN HORMONES AND INCRETIN-BASED THERAPIES:
EFFECTS BEYOND GLYCEMIA
Glucagon like peptide 1(7–36) is produced by intestinal L-cells
in response to meal and is a pluripotent incretin hormone in
humans, which exerts multiple physiological actions (Mojsov
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et al., 1987). GLP-1(7–36) is promptly cleaved by the enzyme
dipeptidyl peptidase-4 (DPP-4) into its inactive form GLP-1(9–
36) (Lovshin and Drucker, 2009). GLP-1 receptors (GLP-1R) are
widely expressed in pancreatic islet cells and in several other tis-
sues. GLP-1 has a wide target tissue distribution and acts through
specific heterotrimeric G-protein complex receptors, function-
ally associated with activation of second messengers such as
adenylate cyclase. GLP-1R belongs to the class B family of 7-
transmembrane-spanning receptors and its expression has been
reported in pancreas,heart,vascular smooth muscle cells, endothe-
lial cells, macrophages and monocytes, lung, kidney, gastrointesti-
nal tract (stomach and intestine), as well as in central (brain) and
in peripheral nervous system. Brain and cardiac tissues express the
same GLP-1R as pancreas, whereas receptors on skeletal muscle,
adipose tissue, and liver bear some degree of homology to pan-
creatic GLP-1R (Rasmussen et al., 2003; Holst and Jens, 2008;
Martin et al., 2011). GLP-1, through its receptor GLP-1R, has
multiple physiological actions (Figure 1), including enhance-
ment of glucose-stimulated insulin secretion by pancreatic β-cells,
inhibition of glucose-dependent glucagon secretion, and control
of appetite and body weight (Kieffer and Habener, 1999).
INCRETIN HORMONES AND DIABETIC VASCULAR COMPLICATIONS
In the light of above-mentioned properties, new drugs based on
incretin effects have been and are being developed for T2DM
treatment. GLP-1R-agonists exert multiple effects on cardiovas-
cular system, such as modulation of blood pressure, of heart rate,
of arterial dilation, of endothelial and myocardial function, and
of myocardial contractility (Vila Petroff et al., 2001; Yamamoto
et al., 2002; Green et al., 2008). Beneficial effects of GLP-1 on
cardiovascular diseases have been reported both in animal mod-
els and in patients, either in the absence or presence of diabetes
(Nikolaidis et al., 2005a,b; Ozyazgan et al., 2005; Sokos et al.,
2006). Binding of GLP-1 to its receptor in the myocardium leads
to an increased production of cyclic adenosine monophosphate
(cAMP) and to an activation of protein kinase A (PKA), which
results into an increased glucose uptake and into inotropic effects
in myocardial tissue. GLP-1 knockout mice exhibit reduced rest-
ing heart rate, elevated left ventricular and diastolic pressure, and
increased left ventricular thickness compared to wild type mice
(Ban et al., 2008). Treatment with GLP-1 or with GLP-1R-agonists
was found to improve left ventricular function (Nikolaidis et al.,
2004; Sokos et al., 2006) and to reduce circulating levels of brain
FIGURE 1 | GLP-1 actions and target organs. GLP-1, through its receptor GLP-1R, has functional effects on a variety of tissues.
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natriuretic peptide (BNP) (Courrèges et al., 2008; Bergenstal et al.,
2010).
Elevated tumor necrosis factor-alpha (TNF-α) levels and hyper-
glycemia are involved in diabetes associated endothelial dysfunc-
tion and may cause premature atherosclerosis (Iwasaki et al.,
2008). TNF-α and hyperglycemia have been shown to induce
plasminogen activator inhibitor-1 (PAI-1) and cell adhesion mol-
ecules (VCAM-1 and ICAM-1) expression in human vascular
endothelial cells (Morigi et al., 1998). Treatment with GLP-1-R
agonists reduces TNF-α-mediated expression of PAI-1, ICAM-1,
and VCAM-1 expression as well as TNF-α induced oxidative stress
in human vascular endothelial cells (Liu et al., 2009; Shiraki et al.,
2012).
Recent experimental studies have shown that GLP-1R activa-
tion by administration of GLP-1 analog exendin-4 significantly
reduces accumulation of monocytes/macrophages in the vascular
wall of C57BL/6 and ApoE−/− mice. This effect seems to be medi-
ated by suppression of the inflammatory response in macrophages
through the activation of cAMP/PKA pathway, which inhibits the
expression of TNF-α and of monocyte chemoattractant protein-
1 (MCP-1), two molecules involved in macrophage recruitment,
an important event in early atherosclerogenesis (Arakawa et al.,
2010).
The relevance of GLP-1 is further supported by the observation
that its receptor is expressed on podocytes, suggesting that GLP-1
may have a potential role in diabetic nephropathy. Up-regulation
of DPP-4 expression in renal glomeruli occurs during inflamma-
tion (Stefanovic et al., 1993), and this phenomenon is associated
with the development of diabetes-induced glomerulosclerosis.
A further observation is that GLP-1Rs were down-regulated in
renal glomeruli and tubules of diabetic rats and DPP-4 inhibition
up-regulated such expression (Liu et al., 2012). Evidence from
investigations with DPP-4 inhibitors in diabetic eNOS knockout
mice (Alter et al., 2012), a model of diabetic nephropathy, suggests
the potential of DPP-4 inhibitors to reduce albumin excretion.
This reduction in albumin excretion is thought to reflect benefi-
cial effects of DPP-4 inhibition on podocytes in a context where
podocyte loss is one of the first events leading to proteinuria
(Sharkovska, 2011).
INCRETIN HORMONES AND CENTRAL NERVOUS SYSTEM
Glucagon like peptide 1 receptor stimulation has been associated
with cytoprotection and reduced apoptosis in several tissue types.
This trophic action was likely mediated by PKA and by phospho-
inositide 3-kinase (PI3K) signaling. GLP-1R stimulation has been
shown to suppress pro-apoptotic protein Bax and to stimulate
anti-apoptotic protein Bcl-2 expression, thereby favorably mod-
ifying Bax/Bcl-2 ratio, supporting cell survival. Pancreas, brain,
and heart have been shown to express the same GLP-1R type and
it may be speculated that this cytoprotective effect may occur in
these tissues (Drucker, 2003; Ban et al., 2010; Li et al., 2010).
Recent studies have further demonstrated neurotrophic and
neuroprotective effects of GLP-1 and GLP-1 analogs on learn-
ing and cognition, including reduced beta-amyloid expres-
sion, improved synaptic plasticity, improved object recognition,
improved spatial learning and memory (Perry et al., 2002; During
et al., 2003).
Specific hypothalamic nuclei serve as control centers for
appetite. The arcuate nucleus lies outside the blood-brain bar-
rier and is the major target for peripheral hormones that regulate
appetite, including GLP-1. This nucleus contains two distinct types
of neurons, anorexigenic and orexigenic, Among Neuropeptide Y-
receptors (NPY-R), NPYR1 and Y5-receptor activation appears
to stimulate appetite, while NPYRY2- and Y4-receptor activation
suppresses food intake via presynaptic inhibition of NPY release.
GLP-1 has been shown to antagonize the orexigenic effects of NPY.
Of note, Neuropeptide Y system is able to regulate bone activ-
ity through specific receptors expressed both on osteoblasts and
osteoclasts (Khor and Baldock, 2012). GLP-1R is also expressed
in neurons projecting both into and out of areas of the cen-
tral nervous system, which are critical to energy balance regu-
lation (Larhammar, 1996; Hahn et al., 1998; Inui, 1999; Chaudhri
et al., 2006; Egan and Margolskee, 2008). Increased GLP-1 lev-
els result into an anorexigenic effect with a significant appetite
reduction for the subsequent meal (Furuse et al., 1997; Kim et al.,
2011).
DIABETES MELLITUS AND BONE
An association between diabetes mellitus and loss of bone mass
due to osteoporosis (OP) has been initially described in the 40s
(Albright and Reifenstein, 1948). This discovery has more recently
received great attention since the presence of OP, in diabetic
patients, can increase morbidity and mortality. In recent years,
several studies were carried out in order to better understand the
effects of DM on bone metabolism (Christensen and Svendnsen,
1999; Gunczler et al., 2001; Strotmeyer et al., 2004).
DIABETES AND BONE MINERAL DENSITY
A low BMD has been reported in T1DM, while in T2DM BMD is
similar to or even higher than in non-diabetic subjects (Isidro
and Ruan, 2010). Nevertheless, experimental evidence clearly
demonstrated an increased fracture risk in T1DM and in T2DM
(Vestergaard, 2007), due to decreased bone mass, altered bone
composition, increased risk of falling, and/or to other factors
such as the pharmacological treatment employed. Of note, the
increased fracture risk was reported only in established T2DM
patients in comparison with subjects with impaired glucose tol-
erance (IGT), a condition that precedes disease onset. Such
difference can be explained by the anabolic effects of insulin
on bone that may have protected IGT individuals from frac-
ture risk. In addition, during disease progression, disease-related
complications, such as glycation of collagen in bone, can con-
tribute to increased bone fragility with consequent major frac-
ture risk despite normal or higher BMD (De Liefde et al.,
2005).
In T1DM and, to a lesser extent in T2DM, fracture risk is
increased for most skeletal sites, such as humerus, hip, or spine; in
T2DM (Vestergaard et al., 2005).
Overall, pathophysiological mechanisms behind above-
mentioned phenomena can be divided into: (a) mechanisms that
decrease BMD or weaken bone structure; (b) mechanisms that
increase the likelihood of falls and of other traumas (Vestergaard,
2007).
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Mechanisms that decrease BMD or weaken bone structure
Mechanisms underlying alterations of bone metabolism and
turnover in DM are still unclear and a number of potential
explanations have been related to the type of diabetes.
Type 1 diabetes mellitus is characterized by an absolute endoge-
nous insulin deficiency, and the finding of osteopenia and OP in
these young patients, has led to hypothesis that insulin exerts an
anabolic action on bone (Thrailkill et al., 2005); indeed, insuffi-
cient skeletal mineralization during puberty has been proposed
as a mechanism that may explain lower BMD in T1DM. This
may be due to changes in insulin secretion resulting in a state
of low bone turnover with a considerable reduction of num-
ber and activity of osteoblasts (Goodman and Hori, 1984). It
has also been proposed that autoimmune and inflammatory phe-
nomena, that precede T1DM onset, may contribute to bone loss
or to altered mineralization during puberty (Räkel et al., 2008).
Moreover, it has been reported that insulin-like growth factor-
1 (IGF-1) may play an important role in the onset of bone
alteration in T1DM due to its anabolic effects in childhood as
well as in adulthood, through a direct action on osteoblasts,
which express insulin and IGF-1 receptors. Of note in T1DM,
serum IGF-1 and IGFBP-3 (IGF-Binding Protein-3) levels are
lower than in T2DM and in non-diabetic patients (Jehle et al.,
1998).
Recent studies have reported low IGF-1 levels together with
high IGFBP-1 and growth hormone (GH) levels in adolescent
T1DM girls with a disease duration >5 years, compared with
controls, especially in the case of poor metabolic control (Moyer-
Mileur et al., 2008). In addition, high blood glucose levels and
disease duration were associated with increased bone resorption
parameters, while low IGF-1 levels could be considered as good
predictors of bone strength. It is important to emphasize that sim-
ilar bone abnormalities have been described also in young diabetic
patients with a fairly good glycemic control, thus reinforcing the
concept that bone tissue is deeply influenced by glycometabolic
control (De Schepper et al., 1998).
The influence of gender on the relationship between T1DM
and OP is controversial, with some studies showing an increased
risk in males vs. females (Strotmeyer et al., 2006); the use of
oral contraceptives and high estrogen levels in premenopausal
women may offer a protection against bone loss associated to
diabetes.
In contrast with T1DM, which is characterized by insulin
deficiency, T2DM is characterized by a state of insulin resis-
tance and high insulin levels, at least in the first phase of the
disease natural history. This may have positive effects on bone,
while established T2DM has a net negative effect on skeletal
integrity (Schwartz, 2009). Moreover, in non-diabetic subjects,
a low Body Mass Index (BMI) is associated with decreased
BMD and with increased risk of OP and of fracture (Espal-
largues et al., 2001). In a meta-analysis Vestergaard (2007) showed
that BMI is also an important predictor of BMD in T2DM,
while overweight and obesity, which are frequent in T2DM, are
believed to be protective factors for BMD (Wang et al., 2005).
These findings led to the hypothesis that, in diabetes, not only
BMD but also bone quality and its microstructure could be
impaired.
Mechanisms that increase the likelihood of falls and of other
traumas
An interesting prospective cohort study (Schwartz et al., 2002)
performed in 9249 women aged ≥67 years analyzed the number
of falls: a total of 629 (6.8%) women had diabetes, including 99
who used insulin. During an average follow-up of 7.2 years, 1640
women (18%) fell more than once a year. Diabetes was associ-
ated with an increased risk of falling for patients not treated with
insulin. In the first 2 years of follow-up, women with diabetes were
not more likely to fall than those without diabetes, but they had
significantly more falls. Women with diabetes were more likely to
have additional risk factors for falls such as poor balance, arthritis,
cardiovascular disease, depression, poor vision, and use of med-
ications for sleeplessness or anxiety. These results indicate that
older women with diabetes have a substantially increased risk for
falls and suggest that fall prevention efforts should be taken into
consideration in the treatment of older women with diabetes.
Another study (Bischoff et al., 2003) showed that a simple,
inexpensive, and well-tolerated intervention such as vitamin D
and calcium administration, may help in reducing the burden of
falling in the elderly. Specifically, this is a double-blind randomized
controlled trial, in which 122 elderly women (mean age 85.3 years)
have been studied in long-stay geriatric care. Participants received
1200 mg calcium plus 800 IU cholecalciferol or 1200 mg calcium
per day over a 12-week treatment period. The number of falls per
person was compared between the treatment groups. The results
showed that vitamin D and calcium supplementation reduced the
number of falls per person by 49%, improved musculoskeletal
function, increased vitamin D status, and decreased PTH secretion
and bone resorption within 3 months of treatment.
ADIPOKINES, DIABETES MELLITUS, AND BONE
The increase in visceral fat tissue, observed in T2DM, is usu-
ally associated to ongoing inflammation, which may contribute
to an increased bone turnover, likely secondary to the release of
adipokines by adipocytes (Baynes et al., 1997; Gysemans et al.,
2002; Schaffler et al., 2006; Reid, 2008). A specific role in bone
metabolism is played by leptin and adiponectin. In T2DM, cir-
culating leptin levels are increased and are able to stimulate
osteoblasts and to inhibit osteoclast formation and activity, thus
promoting osteogenesis. In contrast, leptin seems to have an indi-
rect negative effect on bone formation at the level of the central
nervous system, acting on specific hypothalamic neurons. Con-
sequently, the overall effect of leptin on bone results from the
combination of negative and positive effects (Cirmanová et al.,
2008; Kanazawa et al., 2009). In order to gain insights into the rela-
tionship between fat mass and BMD, an interesting study (Thomas
et al., 2001), performed in premenopausal and postmenopausal
women as well as in men, correlated leptin, insulin, and estrogen
levels with BMD at the total hip, mid-lateral spine, and mid-distal
radius. Results showed a correlation between serum leptin levels
and BMD in women but not in men. Leptin was also negatively
associated with bone turnover, suggesting its protective role against
bone resorption.
As far as adiponectin is concerned, its effect is uncertain and has
been related to bone turnover markers and to BMD (Miazgowski
et al., 2012; Starup-Linde, 2013).
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It is known that acute and chronic hyperglycemia suppress
the expression of genes associated with maturation in mouse
osteoblastic diabetic models, while increasing the expression of
genes such as PPAR, which stimulates the differentiation of mes-
enchymal stem cells in adipocytes (Williams et al., 1997; McCabe,
2007; Merlotti et al., 2010). Indeed, the results of recent experimen-
tal investigations have shown that, similarly to what occurs in other
tissues, a state of chronic hyperglycemia is able to induce non-
enzymatic glycosylation and transformation of various proteins
in advanced glycosylation end products (AGE), especially of type
1 collagen (Botolin and McCabe, 2006). Therefore, hyperglycemia
and high oxidative stress, frequently observed in diabetes, would
lead to formation of cross-glycosylated links to collagen chains
that constitute the bone matrix, leading to a deterioration of bone
mineralization and thus impairing biomechanical properties of
the skeleton. AGEs can also affect bone metabolism by inducing
the expression of pro-inflammatory cytokines such as TNF-alpha
that promote resorption, or by inhibiting osteoblastic activity and
maturation (Katayama et al., 1996; Saito and Marumo, 2010). A
case-control study, performed in T1DM patients and in age- and
sex-matched healthy subjects analyzed bone histomorphometric
and micro-TC data on iliac biopsies. Results revealed no signifi-
cant difference between the two groups, indicating no effects on
bone structure before manifested diabetic complications (Armas
et al., 2012).
It is important to emphasize that recent evidence has shown
that bone tissue can affect carbohydrate metabolism; in particular,
it seems that bone proteins such as osteocalcin (OC) (the main
protein secreted by osteoblasts) can modulate insulin secretion as
well as adiponectin expression in adipocytes, suggesting that bone
secreted molecules might influence insulin secretion and glucose
tolerance in vivo (Lee et al., 2007).
It has been hypothesized that both microangiopathy and
macroangiopathy may contribute to OP and to increased frac-
ture risk. As a matter of fact, diabetes-related comorbidities such
as diabetic retinopathy, peripheral neuropathy, and cerebral stroke
or hypoglycemia may increase the risk of falling. The combina-
tion of poor bone quality and frequent falls would be expected to
increase the risk of fractures independently of BMD (Janghorbani
et al., 2007).
BONE TURNOVER AND DIABETES MELLITUS
Several observations evidenced a condition of low bone turnover
and decreased bone formation both in T1DM and T2DM (Jang-
horbani et al., 2007). A cross-sectional study evaluated serum
levels of bone markers in 78 patients affected by T2DM com-
pared with 55 non-diabetic subjects. Results showed lower levels
of bone resorption markers and of i-PTH in T2DM compared
with healthy subjects, while no difference was detected in bone
formation markers. The hypothesis suggested by authors was that
the lower i-PTH levels induced a low bone turnover state. This
condition may be responsible of higher risk of fractures. How-
ever, conflicting results have been reported about the association
between bone metabolism and T2DM. This can be due to differ-
ent disease duration, influence of other factors such as estrogen,
testosterone, ethnic group, and also the different bone site analyzed
(e.g., cortical vs. cancelous bone) (Reyes-García et al., 2013).
Recently, a great interest has been focused on a new pro-
tein involved in bone formation, sclerostin. This protein is a
secreted Wnt antagonist, produced almost exclusively by osteo-
cytes, that binds to the low-density lipoprotein receptor-related
proteins 5 and 6 (LRP5 and LRP6), thus inhibiting the canon-
ical Wnt/β-catenin signaling pathway and thus osteoblast activ-
ity (McCabe, 2007). Its biological importance is underlined by
both experimental studies in knockout animals and by clini-
cal observations in subjects with sclerosteosis and van Buchem
disease, two genetic disorders with impaired sclerostin produc-
tion and markedly increased bone mass (Moester et al., 2010).
In a recent study we showed (Gennari et al., 2012) a marked
increase in circulating sclerostin levels in T2DM patients, with
mean sclerostin concentrations >2-fold higher than in age- and
sex-matched controls; this increase could represent a possible
cause of reduced bone formation and of impaired bone quality
observed in T2DM. A similar reduction in bone formation was
also observed in T1DM, although sclerostin levels were not dif-
ferent between T1DM patients and control subjects, suggesting
that partially different mechanisms may be involved in the patho-
genesis of skeletal fragility in T1DM and T2DM. These results
have been further confirmed by Gaudio et al. (2012) showing that
sclerostin levels are associated with inhibition of Wnt/β-catenin
signaling and reduced bone turnover in T2DM. In contrast, Jas-
trzebski et al. (2013) did not confirm the correlation between
bone formation and serum sclerostin; however, such study was
performed in mice that, in addition, were not diabetic, therefore
in a quite different setting compared to the previous two studies
(Gaudio et al., 2012; Gennari et al., 2012) that were conducted in
T2DM patients.
Several drugs used for diabetes treatment have an effect on
bone metabolism, not only through their hypoglycemic effect.
Thiazolidinediones (TZD) such as pioglitazone, a peroxisome
proliferator-activated receptor-γ (PPAR-γ) agonist, have recog-
nized negative effects on bone. PPAR-γ is expressed in bone
marrow cells and regulates mesenchymal stem cells differenti-
ation into adipocytes or into osteoblasts. In vitro studies have
shown that TZD stimulate mesenchymal stem cells differentia-
tion into adipocytes rather than into osteoblasts (Ali et al., 2005).
In agreement with these preclinical observations, several clinical
studies demonstrated that long-term therapy with TZD causes
BMD reduction and a great risk of fractures, particularly in females
(Loke et al., 2009).
The use of metformin or sulfonylureas seems to have a posi-
tive effect on bone, with a reduction in fracture risk (Wang et al.,
2005). Sulfonylureas might have a beneficial effect through the
enhancement of IGF-1 secretion; experimental studies with cul-
tured cells showed that metformin stimulates the differentiation
and mineralization of osteoblasts (Kanazawa et al., 2008).
As for insulin, its anabolic effect on bone metabolism is well
established; however, its effects on skeleton remain somehow con-
troversial. Some studies demonstrated that insulin therapy was
associated with a high risk of vertebral fractures (Kanazawa et al.,
2010); this may be due to the fact that, for example, T2DM
patients on insulin therapy are likely to have a long disease
duration and/or complications, or a higher risk of hypoglycemic
events.
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INCRETIN HORMONES AND BONE METABOLISM
Bone turnover is characterized by a dynamic process that requires
energy expenditure derived from meal ingestion. In particular,
during the night, the lack of available nutrients could increase
bone resorption in order to maintain stable levels in circulat-
ing calcium. After food intake, instead, bone resorption becomes
unnecessary and it is consequently inhibited. This event may be
mediated by gastrointestinal hormones released after meal inges-
tion such as GLP-1 and GIP (Henriksen et al., 2009). In line with
this hypothesis, the observation that parenteral feeding is asso-
ciated with reduced bone mass suggests that a deficit in incretin
hormones could have a certain role in bone turnover (Henriksen
et al., 2003).
Interestingly, some studies found that GLP-1 and other incretin
hormones (Figure 2), such as GIP or GLP-2, could have a positive
effects on bone through antiresorptive and anabolic properties,
suggesting a beneficial effects of antidiabetic drugs like GLP-
1R-agonists or DPP-4 inhibitors on bone metabolism (Figure 3,
Table 1). However, the molecular mechanisms involved in such
beneficial effects have not been elucidated and have only been
hypothesized; these appear to involve Wnt/beta-catenin pathway,
Osteoprotegerin (OPG)/RANKL (Receptor activator of nuclear
factor kappa-B ligand) ratio and sclerostin levels.
GIP AND BONE METABOLISM
Bollag et al. investigated the expression of GIP-receptor (GIPR)
in normal rat bone, in osteoblasts, and in osteocytes as well as
in osteoblast-like cell lines, showing the presence of a high affin-
ity, functional GIPR, that acts via cAMP pathway and increasing
intracellular calcium levels. Moreover, GIP increases collagen type
1 expression and alkaline phosphatase activity in osteoblastic-
like cells, consistent with an anabolic effect (Bollag et al., 2000)
of this incretin hormone. These data have been confirmed in
ovariectomized (OVX) rats compared with normal rats: inter-
mittent injection of GIP in these models leads to a significant
increase in lumbar BMD (BMD-L) only in OVX rats. Further-
more, they demonstrated in vitro that GIP action is dose- and
time-dependent; indeed, high GIP concentrations down regulate
GIPR expression in Saos-2 cells within 3 h of exposure; in con-
trast, lower GIP concentrations down regulate GIPR just after a
longer exposure. Therefore, intermittent administration of GIP
seems to have an anabolic effect and to prevent bone loss, simi-
larly to PTH (Bollag et al., 2001). GIP receptors were detected also
in murine osteoclastic-like cells, in which GIP appears to suppress
RANKL-induced bone resorption (Zhong et al., 2007).
Using GIPR knockout mice (GIPR−/−), Xie et al. (2005)
demonstrated a reduction in bone formation and an increase
in bone resorption with a low bone mass; conversely, GIP-
overexpressing transgenic mice exhibited increased bone mass (Xie
et al., 2007).
GLP-1, GLP-2, AND BONE METABOLISM
Additional investigations focused on the specific role of GLP-1
on bone metabolism. Yamada et al. (2008) demonstrated that
FIGURE 2 | Effects of incretin hormones on bone metabolism. Incretin
hormones are secreted by intestinal L-cells and, in minor amounts, by
pancreatic α-cells. Incretin hormones can stimulate osteoblastogenesis
indirectly via increased insulin secretion as well as through a direct action on
osteoblasts. Moreover, incretin hormones can inhibit osteoclastogenesis by
stimulating calcitonin production. CT, calcitonin.
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FIGURE 3 | Effects of incretin-based therapies on bone metabolism.
GLP-1 receptor agonists and DPP-4 inhibitors (via endogenous GLP-1)
may stimulate osteoblastogenesis and inhibit osteoclastogenesis.
Specifically, osteoblastogenesis stimulation has been hypothesized to
occur via activation of Wnt/beta-catenin pathway and/or increased
OPG/RANKL ratio. In addition, osteoclastogenesis inhibition has been
suggested to be mediated by reduced sclerostin levels. GLP-1 RA, GLP-1
receptor agonists; DPP4i, dipeptidyl peptidase-4 inhibitors; OPG,
osteoprotegerin; RANKL, receptor activator of nuclear factor kappa-B
ligand.
GLP-1R−/− mice are characterized by decreased cortical BMD,
measured by quantitative computerized tomography (qTC), and
by increased bone fragility. Moreover, bone histomorphometry
showed that these genetically modified mice display increased
osteoclastic bone resorption activity, which however appears not
secondary to a direct action on osteoclasts. Furthermore, GLP-
1 has also been shown to indirectly inhibit bone resorption via
calcitonin; indeed, it has been reported that GLP-1R is expressed
on thyroid C cells and that GLP-1 is able to stimulate calcitonin
secretion (Lamari et al., 1996). Accordingly, calcitonin deficiency
in GLP-1R−/− mice could lead to increased osteoclastic bone
resorption (Yamada et al., 2008).
In insulin resistant and in type 2 diabetic rats, the occur-
rence of an insulin- and PTH-independent bone anabolic action
mediated by GLP-1 has been demonstrated, together with an
osteogenic action on altered bone structure on osteoblasts. Over-
all, GLP-1 appears to have a double effect on bone metabolism, one
direct and another indirect, the latter via thyroid C cells (Nuche-
Berenguer et al., 2009). An experimental study was performed
in animal models to analyze bone effects of GLP-1 administra-
tion in three different glycometabolic conditions: blood and bone
samples were collected from streptozocin-induced diabetic, from
fructose-induced insulin-resistant rat models, and from normal
control rats, at basal and after 3 days of treatment with GLP-1
or placebo. This study showed an increase in OPG/RANKL ratio
in both experimental models at bone level, but not in plasma.
This difference between bone and plasma may derive from the
acute administration and the short half-life of GLP-1. Neverthe-
less, a beneficial effect on bone structure was indeed observed in
rats with impaired glucose metabolism (Nuche-Berenguer et al.,
2010a).
A relationship between incretin hormones and bone has
been investigated also in humans. Despite some differences with
rodents, studies in vitro demonstrated that GLP-1 can function-
ally interact with human osteoblasts through a receptor different
from GLP-1R described for pancreas (Nuche-Berenguer et al.,
2010b). In osteoblastic MC3T3-EI cells, GLP-1 specifically binds
to cell membrane and promotes the immediate hydrolysis of gly-
cosylphosphatidylinositols (GPIs), thus generating diacylglycerol
and inositol phosphoglycans (IPGs) that act as second messen-
gers. GLP-1 induced phosphorylation in mitogen activated protein
kinase (MAPK) through a cAMP-independent pathway, preferen-
tially stimulated by GLP-1R coupled with G-protein expressed
in other tissues. GLP-1 interaction with MC3T3-EI affected gene
expression, in particular upregulated OC expression, while Wnt/β-
catenin pathway remained unchanged (Nuche-Berenguer et al.,
2010b). It was also described that osteoblastic-like cells, based on
their stage of differentiation, differentially expressed receptors for
gut hormones such as GIP, GLP-1, GLP-2, ghrelin, and obestatin.
Expression of these molecules was assessed on three osteoblastic
cells lines (Saos-2, TE-85, and MG-63) that represent different
stages of osteoblastic development (Pacheco-Pantoja et al., 2011).
Evidence of incretin effects in humans were provided by Henrik-
sen et al. that showed a decrease in nocturnal bone resorption
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Table 1 | Effects of incretin hormones on bone metabolism.
Study subjects Incretin hormones Effects on bone Reference
Postmenopausal women GLP-2 ↑ BMD at cortical bone; ↓ s-CTX;↔
s-calcium and s-phosphorous
Henriksen et al. (2009)
Human osteoblastic-like cells GIP ↑ Collagen type 1; ↑ alkaline phosphatase, ↑
osteoblast-like cell activity
Bollag et al. (2000)
Ovariectomized rats GIP ↑ BMD Bollag et al. (2001)
Murine osteoclastic-like cells GIP ↓ Active bone resorption Zhong et al., 2007
GLP-1R−/− mice GLP-1 ↓ Cortical BMD Yamada et al. (2008)
GPR−/− mice GIP ↓ Bone formation; ↑ bone resorption; ↓ bone
mass
Xie et al. (2005)
GIP-overexpressing transgenic
mice
GIP ↑ Bone mass Xie et al. (2007)
Murine C cell line GLP-1 ↑ Calcitonin and bone resorption Lamari et al. (1996)
Type 2 diabetic rats,
insulin-resistant rats
GLP-1 ↑ OC; ↑ OPG Nuche-Berenguer et al. (2009)
Type 2 diabetic rats,
insulin-resistant rats
Exendin-4 ↑ BMD Nuche-Berenguer et al.
(2010a)
MC3T3-EI osteoblastic cells GLP-1 ↑ OC;↔ OPG Nuche-Berenguer et al., 2010b
Hyperlipidemic rat models GLP-1 or Exendin-4 ↑OPG/RANKL ratio Nuche-Berenguer et al. (2011)
Type 2 diabetic patients Exenatide ↔ BMD Bunck et al. (2011)
Type 2 diabetic patients Vildagliptin ↔ BMD Bunck et al. (2012)
OC, osteocalcin; S-CTX, C-terminal telopeptide region of collagen type I; OPG: osteoprotegerin; BMD, bone mineral density; RANKL: receptor activator of nuclear
factor kappa-B ligand.
after administration of GLP-2 at 10 p.m. In this work, 160 post-
menopausal women were randomized to receive daily doses of
0.4, 1.6, 3.2 mg of GLP-2 or placebo, plus calcium and vitamin D
for 120 days. During this period women were monitored, report-
ing adverse effects and collecting blood and urine samples to
assess safety and efficacy parameters. GLP-2 effects were evaluated
together with circulating markers of bone formation and bone
resorption and also BMD as measured by dual x-ray absorp-
tiometry (DXA). Results reported the absence of any toxic effect
of GLP-2 treatment and, more interestingly, a dose dependent
increase in BMD, statistically significant for 1.6 and 3.2 mg doses
compared to placebo. Injection of GLP-2 determined an imme-
diate and sustained decrease in bone resorption markers such as
C-terminal telopeptide region of collagen type I (s-CTX), while
levels of bone formation markers, like OC, were not affected, thus
providing evidence of a direct action of incretin hormones in regu-
lation of bone metabolism (Henriksen et al., 2009). Subcutaneous
injection of GLP-2 did not affect the same bone markers in colec-
tomized patients with short-bowel syndrome evidencing the key
role of small intestine in this response (Gottschalck et al., 2008).
EXENDIN-4, EXENATIDE, AND BONE METABOLISM
A similar approach was used in the same animal models employ-
ing GLP-1 analog exendin-4 (Ex-4). Also in this case, Ex-4 had
an insulin-independent bone anabolic effect both in diabetic and
in insulin-resistant rats, possibly due to the interaction with Wnt
pathway (Nuche-Berenguer et al., 2010a). Finally, the same authors
used GLP-1 and Ex-4 administration in hyperlipidemic rat models
and observed similar osteogenic effects, thus confirming fat-bone
relationships described previously (Nuche-Berenguer et al., 2011).
A recent study by Kim et al. (2013) investigated cellular and
molecular mechanisms responsible for the increased bone den-
sity following exendin-4 treatment, with specific focus on the
effect of exendin-4 on osteocytes and on sclerostin production.
First of all the presence of GLP-1 receptor was demonstrated,
in vitro, on MLO-Y4 cells, a murine long bone-derived osteocytic
cell line. Moreover, using immunohistochemistry and immuno-
fluorescence, GLP-1R was shown to colocalize with sclerostin on
osteocytes. Through quantitative real time RT-PCR and Western
blot analysis, the authors demonstrated that exendin-4 treatment
on MLO-Y4 cells reduced the production of sclerostin, both in
normal than in high-glucose conditions. In addition, this study
has tested the effects of exendin-4 treatment in vivo on Otsuka
Long Evans Tokushima Fatty (OLETF) rats (a T2DM rat model)
showing an increased femoral BMD together with a decrease of
OC and unchanged levels of TRAP 5b, with a BMI independent
effect. This suggests that a reduction of sclerostin in osteocytes
and an increase of OC in osteoblasts might be related to a BMD
increase (Kim et al., 2013).
Additional evidence of a positive effect of incretin hormones on
bone turnover derived indirectly by data emerging from incretin-
based therapy in T2DM patients. As reported above, T2DM is
associated to an increased fracture risk (Vestergaard, 2007; Merlotti
et al., 2010), and amelioration in bone parameters after incretin
hormone administration has been reported. In a clinical trial,
T2DM patients were randomized to receive GLP-1R-agonist exe-
natide or insulin glargine, added to their metformin-based ther-
apy. The two groups were similar in terms of clinical characteristics
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(age, weight, sex, glycemic control, and markers of bone metabo-
lism) at baseline. After 44 weeks of treatment, patients that received
exenatide had a significant decrease in body weight compared to
those treated with insulin glargine. The different drug regimen
did not affect BMD, as shown by similar levels of BMD in the
two groups at the end of follow-up. These findings suggest that, in
T2DM patients, long-term injection of exenatide will not lead to
an increase in fracture risk (Bunck et al., 2011).
DPP-4 INHIBITORS AND BONE METABOLISM
A neutral role of DPP-4 inhibitors on bone metabolism was
demonstrated by treatment with vildagliptin (100 mg once daily)
in drug naïve type 2 diabetic patients for 1 year. Circulating levels
of markers of bone resorption and calcium homeostasis were unaf-
fected compared with baseline and to placebo (Bunck et al., 2012).
A meta analysis was performed by Monami et al. (2011) on all trials
that enrolled T2DM patients that received DPP-4 inhibitors for at
least 24 weeks: fractures were reported only as adverse effects and
probably not all types of fractures were described carefully; never-
theless, collected data revealed that the total number of fractures
was lower in patients treated with DPP-4 inhibitors, suggesting a
potential protective effect on bone of this class of drugs.
CONCLUDING REMARKS
In conclusion, increasing evidence has shown that bone tissue is
involved in pathophysiology of T2DM (Gaudio et al., 2012) as well
as is a target organ of diabetic chronic complications.
In this complex scenario, several antidiabetic drugs have been
demonstrated to influence bone metabolism. Among such drugs,
the recently developed class of incretin-based therapy (GLP-
1R-agonists and DPP-4 inhibitors), is of particular interest in
the light of the effects of incretin hormones on bone metab-
olism. Specifically, data so far available both from experimen-
tal animal models and man, indicate that the beneficial “extra-
glycemic” effects of this class of drugs include the effects on
bone metabolism, that either directly on bone cells or indirectly
(e.g., via thyroid C cells and calcitonin), appear to favor bone
formation and to inhibit bone resorption, thus improving bone
strength.
Further experimental and long-term clinical studies will be
required to confirm the above-mentioned effects and to identify
the underlying pathogenetic mechanisms. This could be particu-
larly important not only for a better understanding of the causes
of skeletal fragility in diabetes but also for its potential therapeutic
implications.
REFERENCES
Ahren, B. (2003). Gut peptides and
type 2 diabetes mellitus treat-
ment. Curr. Diab. Rep. 3, 365–372.
doi:10.1007/s11892-003-0079-9
Albright, F., and Reifenstein, E. C.
(1948). Bone development in dia-
betic children: a Roentgen study.Am.
J. Med. Sci. 174, 313–319.
Ali, A. A., Weinstein, R. S., Stew-
art, S. A., Parfitt, A. M., Monoloa-
gas, S. C., and Jilka, R. I. (2005).
Rosiglitazone causes bone loss in
mice by suppressing osteoblast
differentiation and bone forma-
tion. Endocrinology 146, 1226–1235.
doi:10.1210/en.2004-0735
Alter, M., Ott, I. M., von Websky,
K., Tsuprykov, O., Sharkovska,
Y., Krause-Relle, K., et al. (2012).
DPP-4 inhibition on top of
angiotensin receptor blockade
offers a new therapeutic approach
for diabetic nephropathy. Kidney
Blood Press. Res. 36, 119–130.
doi:10.1159/000341487
Arakawa, M., Mita, T., Azuma, K.,
Ebato, C., Goto, H., Nomiyama, T.,
et al. (2010). Inhibition of mono-
cyte adhesion to endothelial cells and
attenuation of atherosclerotic lesion
by a glucagon-like peptide-1 recep-
tor agonist, exendin-4. Diabetes 59,
1030–1037. doi:10.2337/db09-1694
Armas, L. A., Akhter, M. P., Drin-
cic, A., and Recker, R. R. (2012).
Trabecular bone histomorphome-
try in humans with Type 1 dia-
betes mellitus. Bone 50, 91–96.
doi:10.1016/j.bone.2011.09.055
Ban, K., Kim, K. H., Cho, C. K.,
Sauvé, M., Diamandis, E. P., Backx,
P. H., et al. (2010). Glucagon-
like peptide (GLP)-1(9-36) amide-
mediated cytoprotection is blocked
by exendin(9-39) yet does not
require the known GLP-1 recep-
tor. Endocrinology 151, 1520–1531.
doi:10.1210/en.2009-1197
Ban, K., Noyan-Ashraf, M. H., Hoefer,
J., Bolz, S. S., Drucker, D. J., and
Husain, M. (2008). Cardioprotec-
tive and vasodilatory actions of
glucagon-like peptide 1 receptor are
mediated through both glucagon-





Baynes, K. C., Boucher, B. J., Fes-
kens, E. J., and Kromhout, D.
(1997). Vitamin D, glucose toler-
ance and insulinaemia in elderly
men. Diabetologia 40, 344–347.
doi:10.1007/s001250050685
Bergenstal, R. M., Wysham, C., Mac-
Conell, L., Malloy, J., Walsh, B.,
Yan, P., et al. (2010). Efficacy and
safety of exenatide once weekly ver-
sus sitagliptin or pioglitazone as an
adjunct to metformin for treatment
of type 2 diabetes (DURATION-
2): a randomised trial. Lancet
376, 431–439. doi:10.1016/S0140-
6736(10)60590-9
Bischoff, H. A., Stähelin, H. B., Dick,
W., Akos, R., Knecht, M., Salis, C.,
et al. (2003). Effects of vitamin D
and calcium supplementation on
falls: a randomized controlled trial.
J. Bone Miner. Res. 18, 343–351.
doi:10.1359/jbmr.2003.18.2.343
Bollag, R. J., Zhon, Q., Ding, K. H.,
Phillips, P., Zhong, L., Qin, F.,
et al. (2001). Glucose-dependent
insulinotropic peptide is an inte-
grative hormone with osteotropic
effects. Mol. Cell. Endocrinol.
177, 35–41. doi:10.1016/S0303-
7207(01)00405-1
Bollag, R. J., Zhong, Q., Phillips,
P., Min, L., Zhong, L.,






Botolin, S., and McCabe, R. (2006).
Chronic hyperglycemia osteoblast
modulates gene expression through
osmotic and non-osmotic path-
ways. J. Cell. Biochem. 99, 411–424.
doi:10.1002/jcb.20842
Bunck, M. C., Eliasson, B., Cornér,
A., Heine, R. J., Shaginian, R. M.,
Taskinen, M. R., et al. (2011). Exe-
natide treatment did not affect bone
mineral density despite body weight
reduction in patients with type
2 diabetes. Diabetes Obes. Metab.
13, 374–377. doi:10.1111/j.1463-
1326.2010.01355.x
Bunck, M. C., Poelma, M., Eekhoff,
E. M., Schweizer, A., Heine,
R. J., Nijpels, G., et al. (2012).
Vildagliptin effects on postprandial
markers of bone resorption and
calcium homeostasis in recently
diagnosed, well-controlled, type
2 diabetes patients. J. Diabetes
4, 181–185. doi:10.1111/j.1753-
0407.2011.00168.x
Butler, A. E., Janson, J., Bonner-
Weir, S., Ritzel, R., Rizza, R. A.,
and Butler, P. C. (2003). Beta-
cell deficit and increased beta-cell
apoptosis in humans with type
2 diabetes. Diabetes 52, 102–110.
doi:10.2337/diabetes.52.1.102
Chaudhri, O., Small, C., and Bloom,
S. (2006). Gastrointestinal hor-
mones regulating appetite.
Philos. Trans. R. Soc. Lond.
B Biol. Sci. 361, 1187–1209.
doi:10.1098/rstb.2006.1856
Christensen, J. O., and Svendnsen,




contractors. Osteoporos. Int. 10,
307–311. doi:10.1007/s00198005
0232
Cirmanová, V., Bayer, M., Stárka, L., and
Zajícková, K. (2008). The effect of
leptin on bone: an evolving concept
of action. Physiol. Res. 57(Suppl. 1),
S143–S145.
Courrèges, J. P., Vilsbøll, T., Zdravkovic,
M., Le-Thi, T., Krarup, T., Schmitz,
O., et al. (2008). Beneficial effects
of once-daily liraglutide, a human
glucagons like peptide-1 ana-
logue, on cardiovascular risk
biomarkers inpatients with type
2 diabetes. Diabet. Med. 25,
1129–1131. doi:10.1111/j.1464-
5491.2008.02484.x

























































Ceccarelli et al. Incretin hormones and bone metabolism
De Liefde, I. I., van der Klift, M., de
Laet, C. E., van Daele, P. L., Hof-
man, A., and Pols, H. A. (2005).
Bone mineral density and fracture
risk in type-2 diabetes mellitus: the
Rotterdam Study. Osteoporos. Int.
16, 1713–1720. doi:10.1007/s00198-
005-1909-1
De Schepper, J., Smiths, J., Rosseneu,
S., Bollen, P., and Luis, O. (1998).
Lumbar spine bone mineral den-
sity in children with recent onset
diabetes. Horm. Res. 50, 193–196.
doi:10.1159/000023273
Drucker, D. J. (2003). Glucagon-like
peptides: regulators of cell prolif-
eration, differentiation, and apop-
tosis. Mol. Endocrinol. 17, 161–171.
doi:10.1210/me.2002-0306
During, M. J., Cao, L., Zuzga, D. S., Fran-
cis, J. S., Fitzsimons, H. L., Jiao, X.,
et al. (2003). Glucagon-like peptide-
1 receptor is involved in learning
and neuroprotection. Nat. Med. 9,
1173–1179. doi:10.1038/nm919
Egan, J. M., and Margolskee, R. F.
(2008). Taste cells of the gut
and gastrointestinal chemosen-
sation. Mol. Interv. 8, 78–81.
doi:10.1124/mi.8.2.5
Espallargues, M., Sampietro-Colom, L.,
Estrada, M. D., Solà, M., del Rio,
L., Setoain, J., et al. (2001). Iden-
tifying bone-mass-related risk fac-
tors for fracture to guide bone
densitometry measurements: a sys-
tematic review for the litera-
ture. Osteoporos. Int. 12, 811–822.
doi:10.1007/s001980170031
Furuse, M., Matsumoto, M., Mori,
R., Sugahara, K., Kano, K., and
Hasegawa, S. (1997). Influence of
fasting and neuropeptide Y on the
suppressive food intake induced
by intracerebroventricular injec-
tion of glucagon-like peptide-1
in the neonatal chick. Brain Res.
764, 289–292. doi:10.1016/S0006-
8993(97)00623-9
Gaudio, A., Privitera, F., Battaglia, K.,
Torrisi, V., Sidoti, M. H., Pulvirenti,
I., et al. (2012). Sclerostin levels asso-
ciated with inhibition of the Wnt/(-
catenin signaling and reduced bone
turnover in type 2 diabetes mel-
litus. J. Clin. Endocrinol. Metab.
97, 3744–3750. doi:10.1210/jc.2012-
1901
Gennari, L., Merlotti, D., Valenti, R.,
Ceccarelli, E., Ruvio, M., Pietrini, M.
G., et al. (2012). Circulating scle-
rostin levels and bone turnover in
type 1 and type 2 diabetes. J. Clin.
Endocrinol. Metab. 97, 1737–1744.
doi:10.1210/jc.2011-2958
Giorgino, F., Laviola, L., and Leonar-
dini, A. (2005). Pathophysiology
of type 2 diabetes: rationale for
different oral antidiabetic treat-
ment strategies. Diabetes Res.
Clin. Pract. 68(Suppl.1), S22–S29.
doi:10.1016/j.diabres.2005.03.012
Goodman, W. G., and Hori, M. T.
(1984). Dimished bone formation
in experimental diabetes. Relation-
ship to osteoid maturation and min-
eralization. Diabetes 33, 825–833.
doi:10.2337/diabetes.33.9.825
Gottschalck, I. B., Jeppesen, P. B.,
Hartmann, B., Holst, J. J., and
Henriksen, D. B. (2008). Effects
of treatment with glucagon-like
peptide-2 on bone resorption in
colectomized patients with distal
ileostomy or jejunostomy and
short bowel syndrome. Scand.
J. Gastroenterol. 43, 1304–1310.
doi:10.1080/00365520802200028
Green, B. D., Hand, K. V., Dougan,
J. E., McDonnell, B. M., Cassidy,
R. S., and Grieve, D. J. (2008).
GLP-1 and related peptides cause
concentration-dependent relaxation
of rat aorta through a pathway
involving KATP and cAMP. Arch.
Biochem. Biophys. 478, 136–142.
doi:10.1016/j.abb.2008.08.001
Gunczler, P., Lanes, R., Paoli, M., Marti-
nis, R., Villaroel, O., and Weisinger, J.
R. (2001). Decreased bone mineral
density and bon formation mark-
ers shortly after diagnosis of clini-
cal type 1 diabetes mellitus. J. Pedi-
atr. Endocrinol. Metab. 14, 525–528.
doi:10.1515/JPEM.2001.14.5.525
Gysemans, C., Van Etten, E., Over-
bergh, L., Verstuyf, A., Waer, M.,
Bouillon, R., et al. (2002). Treat-
ment of autoimmune diabetes
recurrence in non-obese diabetic
mice by mouse interferon-beta
in combination with an analogue
of 1alpha,25-dihydroxyvitamin-
D3. Clin. Exp. Immunol. 128,
213–220. doi:10.1046/j.1365-
2249.2002.01825.x
Hahn, T. M., Breininger, J. F., Baskin,
D. G., and Schwartz, M. W. (1998).
Coexpression of AgRP and NPY in
fasting-activated hypothalamic neu-
rons. Nat. Neurosci. 1, 271–272.
doi:10.1038/1082
Hamann, C., Kirschner, S., Gün-
ther, K. P., and Hofbauer, L. C.
(2012). Bone, sweet bone – osteo-
porotic fractures in diabetes melli-
tus.Nat. Rev. Endocrinol. 8, 297–305.
doi:10.1038/nrendo.2011.233
Henriksen, D. B., Alexandersen, P.,
Bjarnason, N. H., Vilsboll, T.,
Hartmann, B., Henriksen, E. E.,
et al. (2003). Role of gastroin-
testinal hormones in postprandial
reduction of bone resorption. J.
Bone Miner. Res. 18, 2180–2189.
doi:10.1359/jbmr.2003.18.12.2180
Henriksen, D. B., Alexandersen, P.,
Hartmann, B., Adrian, C. L.,
Byrjalsen, I., Bone, H. G., et al.
(2009). Four-month treatment with
GLP-2 significantly increases hip
BMD. A randomized, placebo-
controlled, dose-ranging study
in postmenopausal women with
low BMD. Bone 45, 833–842.
doi:10.1016/j.bone.2009.07.008
Holst, J. J., and Jens, J. (2008). The
physiology and pharmacology of
incretins in type 2 diabetes mellitus.
Diabetes Obes. Metab. 10(Suppl.
3), 14–21. doi:10.1111/j.1463-
1326.2008.00920.x
Inui, A. (1999). Neuropeptide Y feed-
ing receptors: are multiple sub-
types involved? Trends Pharmacol.
Sci. 20, 43–46. doi:10.1016/S0165-
6147(99)01303-6
Isidro, M. L., and Ruan, B. (2010).
Bone disease in diabetes.
Curr. Diabetes Rev. 6, 144–155.
doi:10.2174/157339910791162970
Iwasaki, H., Okamoto, R., Kato, S., Kon-
ishi, K., Mizutani, H., Yamada, N.,




activation in bovine aortic endothe-
lial cells. Atherosclerosis 196, 22–28.
doi:10.1016/j.atherosclerosis.2006.12.025
Janghorbani, M., Van Dam, R. M., Wil-
lett, W. C., and Hu, F. B. (2007).
Systematic review of type 1 and type
2 diabetes mellitus and risk of frac-
ture.Am. J. Epidemiol. 166, 495–505.
doi:10.1093/aje/kwm106
Jastrzebski, S., Kalinowski, J., Stolina,
M., Mirza, F., Torreggiani, E., Kala-
jzic, I., et al. (2013). Changes in
bone sclerostin levels in mice after
ovariectomy vary independently of
changes in serum sclerostin levels.
J. Bone Miner. Res. 28, 618–626.
doi:10.1002/jbmr.1773
Jehle, P. M., Jehle, D. R., Mohan, S.,
and Bohm, B. O. (1998). Serum
levels of insulin-like growth fac-
tor system components and rela-
tionship to bone metabolism in
type 1 and type 2 diabetes mellitus
patients. J. Endocrinol. 159, 297–306.
doi:10.1677/joe.0.1590297
Kanazawa, I., Yamaguchi, T., Yamamoto,
M., and Sugimoto, T. (2010).
Relationship between treatments
with insulin and oral hypoglycemic
agents versus the presence of ver-
tebral fractures in type 2 diabetes
mellitus. J. Bone Miner. Metab.
28, 554–560. doi:10.1007/s00774-
010-0160-9
Kanazawa, I., Yamaguchi, T., Yamamoto,
M., Yamauchi, M., Yano, N., and
Sugimoto, T. (2009). Relationships
between serum adiponectin levels
versus bone mineral density, bone
metabolic markers, and vertebral
fractures in type 2 diabetes melli-
tus. Eur. J. Endocrinol. 160, 265–273.
doi:10.1530/EJE-08-0642
Kanazawa, I., Yamaguchi, T., Yano,
S., Yamauchi, M., and Sugimoto,
T. (2008). Metformin enhances
the differentiation and mineral-
ization of osteoclastic MC3T3-
E1 cells via AMP kinase acti-
vation as well as eNOS and
BMP-2 expression. Biochem. Bio-
phys. Res. Commun. 375, 414–419.
doi:10.1016/j.bbrc.2008.08.034
Katayama,Y.,Akatsu, T., and Yamamoto,
M. (1996). Role of nonenzy-
matic glycosylation of type 1 col-
lagen in diabetic osteopenia. J.
Bone Miner. Res. 11, 931–937.
doi:10.1002/jbmr.5650110709
Khor, E. C., and Baldock, P. (2012).
The NPY system and its neural and
neuroendocrine regulation of bone.
Curr. Osteoporos. Rep. 10, 160–168.
doi:10.1007/s11914-012-0102-7
Kieffer, T. J., and Habener, J. F.
(1999). The glucagon-like pep-
tides. Endocr. Rev. 20, 876–913.
doi:10.1210/er.20.6.876
Kim, G. W., Lin, J. E., Valentino,
M. A., Colon-Gonzalez, F., and
Waldman, S. A. (2011). Regulation
of appetite to treat obesity. Exp.
Rev. Clin. Pharmacol. 4, 243–259.
doi:10.1586/ecp.11.3
Kim, J. Y., Lee, S. K., Jo, K. J., Song,
D. Y., Lim, D. M., Park, K. Y., et
al. (2013). Exendin-4 increases bone
mineral density in type 2 diabetic
OLEFT rats potentially through the
down-regulation of SOST/sclerostin
in osteocytes. Life Sci. 92, 533–540.
doi:10.1016/j.lfs.2013.01.001
Lamari, Y., Boissard, C., Moukhtar, M.
S., Jullienne, A., Rosselin, G., and
Garel, J. M. (1996). Expression of
glucagon-like peptide 1 receptor in a
murine C cell line: regulation of cal-
citonin gene by glucagon-like pep-
tide 1. FEBS Lett. 393, 248–252.
doi:10.1016/0014-5793(96)00895-2
Larhammar, D. (1996). Structural diver-
sity of receptors for neuropeptide Y,
peptide YY and pancreatic polypep-
tide. Regul. Pept. 65, 165–174.
doi:10.1016/0167-0115(96)00110-3
Lee, N. K., Sowa, H., Hinoi, E.,
Ferron, M., Ahn, J. D., Con-
favreux, C., et al. (2007). Energy
metabolism by endocrine regula-
tion of skeleton. Cell 130, 456–469.
doi:10.1016/j.cell.2007.05.047
Li, Y., Tweedie, D., Mattson, M. P.,
Holloway, H. W., and Greig, N.
H. (2010). Enhancing the GLP-
1 receptor signaling pathway

























































Ceccarelli et al. Incretin hormones and bone metabolism
leads to proliferation and
neuroprotection in human neurob-
lastoma cells. J. Neurochem. 113,
1621–1631. doi:10.1111/j.1471-
4159.2010.06731.x
Liu, H., Dear, A. E., Knudsen, L. B.,
and Simpson, R. W. (2009). A
long-acting glucagon-like peptide-1
analogue attenuates induction of
plasminogen activator inhibitor
type-1 and vascular adhesion mol-
ecules. J. Endocrinol. 201, 59–66.
doi:10.1677/JOE-08-0468
Liu, W. J., Xie, S. H., Liu, Y.
N., Kim, W., Jin, H. Y., Park,
S. K., et al. (2012). Dipeptidyl
peptidase IV inhibitor attenuates
kidney injury in streptozotocin-
induced diabetic rats. J. Phar-
macol. Exp. Ther. 340, 248–255.
doi:10.1124/jpet.111.186866
Loke, Y. K., Songh, S., and Furberg, C.
D. (2009). Long term use if thiazo-
lidinediones and fractures in type 2
diabetes: a meta analysis. CMAJ 180,
32–39. doi:10.1503/cmaj.080486
Lovshin, J. A., and Drucker, D.
J. (2009). Incretin-based thera-
pies for type 2 diabetes mellitus.
Nat. Rev. Endocrinol. 5, 262–269.
doi:10.1038/nrendo.2009.48
Marchetti, P., Dotta, F., Lauro, D., and
Purrello, F. (2008). An overview
of pancreatic beta-cell defects in
human type 2 diabetes: implications
for treatment.Regul. Pept. 146, 4–11.
doi:10.1016/j.regpep.2007.08.017
Marchetti, P., Lupi, R., Bugliani, M.,
Kirkpatrick, C. L., Sebastiani, G.,
Grieco, F. A., et al. (2012). A
local glucagon-like peptide 1 (GLP-
1) system in human pancreatic
islets. Diabetologia 55, 3262–3272.
doi:10.1007/s00125-012-2716-9
Martin, J. H., Deacon, C. F., Gorrell, M.
D., and Prins, J. B. (2011). Incretin-
based therapies: review of the phys-
iology, pharmacology and emerg-
ing clinical experience. Intern. Med.
J. 41, 299–307. doi:10.1111/j.1445-
5994.2011.02439.x
McCabe, L. R. (2007). Understand-
ing the pathology and mecha-
nisms of type 1 diabetic bone loss.
J. Cell. Biochem. 102, 1343–1357.
doi:10.1002/jcb.21573
Merlotti, D., Gennari, L., Dotta,
F., Lauro, D., and Nuti, R.
(2010). Mechanisms of impaired
bone strength in type 1 and
2 diabetes. Nutr. Metab. Car-
diovasc. Dis. 20, 683–690.
doi:10.1016/j.numecd.2010.07.008
Miazgowski, T., Noworyta-Zietara,
M., Safranow, K., Ziemak, J.,
and Widecka, K. (2012). Serum
adiponectin, bone mineral density
and bone turnover markers in
post-menopausal women with
newly diagnosed type 2 diabetes:
a 12-month follow-up. Diabet.
Med. 29, 62–69. doi:10.1111/j.1464-
5491.2011.03381.x
Moester, M. J., Papapoulos, S. E.,
Löwik, C. W., and van Bezooijen,
R. L. (2010). Sclerostin: current
knowledge and future perspec-
tives. Calcif. Tissue Int. 87, 99–107.
doi:10.1007/s00223-010-9372-1
Mojsov, S., Weir, G. C., and Habener, J.
F. (1987). Insulinotropin: glucagon-
like peptide I (7-37) co-encoded in
the glucagon gene is a potent stim-
ulator of insulin release in the per-
fused rat pancreas. J. Clin. Invest. 79,
616–619. doi:10.1172/JCI112855
Monami, M., Dicembrini, I., Antenore,
A., and Mannucci, E. (2011).
Dipeptidyl peptidase-4 inhibitors
and bone fractures: a meta-analysis
of randomized clinical trials.
Diabetes Care 34, 2474–2476.
doi:10.2337/dc11-1099
Morigi, M., Angioletti, S., Imberti,
B., Donadelli, R., Micheletti,
G., Figliuzzi, M., et al. (1998).
Leukocyte-endothelial inter-
action is augmented by high
glucose concentrations and
hyperglycemia in a NF-kB-
dependent fashion. J. Clin. Invest.
101, 1905–1915. doi:10.1172/JC
I656
Moyer-Mileur, L. J., Slater, H., Jordan,
K. C., and Murray, M. A. (2008).
IGF-1 and IGF-Binding proteins and
bone mass, geometry, and strength:
relation to metabolic control in ado-
lescent girls with type 1 diabetes.
J. Bone Miner. Res. 23, 1884–1891.
doi:10.1359/jbmr.080713
Nikolaidis, L. A., Doverspike, A., Hen-
tosz, T., Zourelias, L., Shen, Y. T.,
Elahi, D., et al. (2005a). Glucagon-
like peptide-1 limits myocardial
stunning following brief coro-
nary occlusion and reperfusion
in conscious canines. J. Phar-
macol. Exp. Ther. 312, 303–308.
doi:10.1124/jpet.104.073890
Nikolaidis, L. A., Elahi, D., Shen, Y.
T., and Shannon, R. P. (2005b).
Active metabolite of GLP-1 medi-
ates myocardial glucose uptake
and improves left ventricu-
lar performance in conscious
dogs with dilated cardiomy-
opathy. Am. J. Physiol. Heart
Circ. Physiol. 289, 2401–2408.
doi:10.1152/ajpheart.00347.2005
Nikolaidis, L. A., Mankad, S., Sokos,
G. G., Miske, G., Shah, A.,
Elahi, D., et al. (2004). Effects
of glucagon-like peptide-1 in
patients with acute myocardial
infarction and left ventricular
dysfunction after successful riper-
fusion. Circulation 109, 962–965.
doi:10.1161/01.CIR.0000120505.91
348.58
Nuche-Berenguer, B., Lozano, D.,
Gutiérrez-Rojas, I., Moreno, P.,
Mariñoso, M. L., Esbrit, P., et
al. (2011). GLP-1 and exendin-4
can reverse hyperlipidic-related
osteopenia. J. Endocrinol. 209,
203–210. doi:10.1530/JOE-11-0015
Nuche-Berenguer, B., Moreno, P., Esbrit,
P., Dapía, S., Caeiro, J. R., Cancelas,
J., et al. (2009). Effect of GLP-1 treat-
ment on bone turnover in normal,
type 2 diabetic, and insulin-resistant
states. Calcif. Tissue Int. 84, 453–461.
doi:10.1007/s00223-009-9220-3
Nuche-Berenguer, B. P., Moreno,
S., Portal-Nunez, S., Esbrit, P.,
and Villanueva-Penacarrillo, M.
L. (2010a). Exendin-4 exerts
osteogenic actions in insulin-
resistant and type 2 diabetic
states. Regul. Pept. 159, 61–66.
doi:10.1016/j.regpep.2009.06.010
Nuche-Berenguer, B., Portal-Núñez,
S., Moreno, P., González, N.,
Acitores, A., López-Herradón,
A., et al. (2010b). Presence of a
functional receptor for GLP-1 in
osteoblastic cells, independent of
the cAMP-linked GLP-1 receptor.
J. Cell. Physiol. 225, 585–592.
doi:10.1002/jcp.22243
Ozyazgan, S., Kutluata, N., Afsar, S.,
Ozdas, S. B., and Akkan, A. G.
(2005). Effect of glucagon-like
peptide-1(7-36) and exendin-
4 on the vascular reactivity in
streptozotocin/nicotinamide-
induced diabetic rats. Pharmacology
74, 119–126.
Pacheco-Pantoja, E. L., Ranganath, L.
R., Gallagher, J. A., Wilson, P. J. M.,
and Fraser, W. D. (2011). Receptors
and effects of gut hormones in three
osteoblastic cell lines. BMC Physiol.
11:12. doi:10.1186/1472-6793-11-12
Perry, T., Haughey, N. J., Mattson, M. P.,
Egan, J. M., and Greig, N. H. (2002).
Protection and reversal of excito-
toxic neuronal damage by glucagon-
like peptide-1 and exendin-4. J.
Pharmacol. Exp. Ther. 302, 881–888.
doi:10.1124/jpet.102.037481
Räkel, A., Sheehy, O., Rahme, E.,
and LeLorier, J. (2008). Osteo-
porosis among patients with
type 1 and type 2 diabetes.
Diabetes Metab. 34, 193–205.
doi:10.1016/j.diabet.2007.10.008
Rasmussen, H. B., Branner, S.,Wiberg, F.
C., and Wagtmann, N. (2003). Crys-
tal structure of human dipeptidyl
peptidase IV/CD26 in complex with
a substrate analog. Nat. Struct. Biol.
10, 19–25. doi:10.1038/nsb882
Reid, I. R. (2008). Relation-
ships between fat and bone.
Osteoporos. Int. 19, 595–606.
doi:10.1007/s00198-007-0492-z
Reyes-García, R., Rozas-Moreno, P.,
López-Gallardo, G., García-Martín,
A., Varsavsky, M., Avilés-Perez, M.
D., et al. (2013). Serum levels
of bone resorption markers are
decreased in patients with type 2
diabetes. Acta Diabetol. 50, 47–52.
doi:10.1007/s00592-011-0347-0
Saito, M., and Marumo, K. (2010). Col-
lagen cross links as a determinant
of bone quality: a possible expla-
nation for bone fragility in again,
osteoporosis, and diabetes melli-
tus. Osteoporos. Int. 21, 195–214.
doi:10.1007/s00198-009-1066-z
Schaffler, A., Muller-Ladner, U.,
Scholmerich, J., and Buchler, C.
(2006). Role of adipose tissue as
an inflammatory organ in human
diseases. Endocr. Rev. 27, 449–467.
doi:10.1210/er.2005-0022
Schwartz, A. V. (2009). Impact of dia-
betes and its treatment on bone.
Clin. Rev. Bone Miner. Metab. 7,
249–260. doi:10.1007/s12018-009-
9049-3
Schwartz, A. V., Hillier, T. A., Sell-
meyer, D. E., Resnick, H. E., Gregg,
E., Ensrud, K. E., et al. (2002).
Older women with diabetes have a
higher risk of falls: a prospective
study. Diabetes Care 25, 1749–1754.
doi:10.2337/diacare.25.10.1749
Sharkovska, Y. (2011). “Linagliptin
offers a new therapeutic approach
for ARB-resistant diabetic
nephropathy,” in 72nd Sci Sess
of the American Diabetes Associa-
tion (ADA) (Alexandra: American
Diabetes Association), 986.
Shiraki, A., Oyama, J., Komoda, H.,
Asaka, M., Komatsu, A., Sakuma,
M., et al. (2012). The glucagon-
likepeptide1analog liraglutide
reduces TNF-(-induced oxida-
tive stress and inflammation
in endothelial cells. Athero-
sclerosis 221, 375–382. doi:10.
1016/j.atherosclerosis.2011.12.039
Sokos, G. G., Nikolaidis, L. A., Mankad,
S., Elahi, D., and Shannon, R.
P. (2006). Glucagon-like peptide-1
infusion improves left ventricular
ejection fraction and functional sta-
tus in patients with chronic heart
failure. J. Card. Fail. 12, 694–699.
doi:10.1016/j.cardfail.2006.08.211
Starup-Linde, J. (2013). Diabetes,
biochemical markers of bone
turnover, diabetes control, and
bone. Front. Endocrinol. 4:21.
doi:10.3389/fendo.2013.00021
Stefanovic, V., Ardaillou, N., Vla-
hovic, P., Placier, S., Ronco, P.,

























































Ceccarelli et al. Incretin hormones and bone metabolism
and Ardaillou, R. (1993). Interferon-
gamma induces dipeptidylpeptidase
IV expression in human glomeru-
lar epithelial cells. Immunology 80,
465–470.
Strotmeyer, E. S., Cauley, J. A., Orchard,
T. J., Steenkiste, A. R., and Dor-
man, J. S. (2006). Middle-aged
premenopausal women with type 1
diabetes have lower bone mineral
density and calcaneal quantita-
tive ultrasound than nondiabetic
women. Diabetes Care 29, 306–311.
doi:10.2337/diacare.29.02.06.dc05-
1353
Strotmeyer, E. S., Cauley, J. A., Schwartz,
A. V., Nevitt, M. C., Resnick, H. E.,
Zmuda, J. M., et al. (2004). Dia-
betes is associated independently of
body composition with BMD and
bone volume in older white and
black men and women: the health,
aging and body composition study.
J. Bone Miner. Res. 19, 1084–1091.
doi:10.1359/JBMR.040311
Thomas, T., Burguera, B., Melton, L.
J. III, Atkinson, E. J., O’Fallon,
W. M., Riggs, B. L., et al. (2001).
Role of serum leptin, insulin, and
estrogen levels as potential medi-
ators of the relationship between
fat mass and bone mineral den-
sity in men versus women. Bone
29, 114–120. doi:10.1016/S8756-
3282(01)00487-2
Thrailkill, K. M., Lumpkin, K., Clay
Bunn, R., Kemp, S., and Fowlkes,
J. L. (2005). Is insulin an anabolic
agent in bone? Dissecting the
diabetic bone for clues. Am. J.
Physiol. Endocrinol. Metab. 289,
E735–E745. doi:10.1152/ajpendo.
00159.2005
Vestergaard, P. (2007). Discrepancies in
bone mineral density and fracture
risk in patients with type 1
and type 2 diabetes-a metanaly-
sis. Osteoporos. Int. 18, 427–444.
doi:10.1007/s00198-006-0253-4
Vestergaard, P., Rejnmark, L., and
Mosekilde, L. (2005). Relative frac-
ture risk inb patients with diabetes
mellitus and the impact of insulin
and oral antidiabetic medication on
relative fracture risk. Diabetologia
48, 1292–1299. doi:10.1007/s00125-
005-1786-3
Vila Petroff, M. G., Egan, J. M.,Wang, X.,
and Sollott, S. J. (2001). Glucagon-
like peptide-1 increases cAMP but
fails to augment contraction in
adult rat cardiac myocytes. Circ. Res.
89, 445–452. doi:10.1161/hh1701.
095716
Wang, M. C., Bachrach, L. K., Van
Loan, M., Hudes, M., Flegal, K.
M., and Crawford, P. B. (2005).
The relative of lean tissue mass
and fat mass to bone density in
young women. Bone 37, 474–481.
doi:10.1016/j.bone.2005.04.038
Williams, J. P., Blair, H. C., McDonald,
J. M., McKenna, M. A., Jordan, S. E.,
Williford, J., et al. (1997). Regulation
of osteoclast bone resorption
by glucose. Biochem. Biophys.
Res. Commun. 235, 646–651.
doi:10.1006/bbrc.1997.6795
Xie, D., Cheng, H., Hamrick, M.,
Zhong, Q., Ding, K. H., Correa,
D., et al. (2005). Glucose-dependent
insulinotropic polypeptide recep-
tor knockout mice have altered
bone turnover. Bone 37, 759–769.
doi:10.1016/j.bone.2005.06.021
Xie, D., Zhong, Q., Ding, K.
H., Cheng, H., Williams,
S., Correa, D., et al. (2007).
Glucose-dependent insulinotropic
peptide-overexpressing transgenic
mice have increased bone mass.Bone
40, 1352–1360. doi:10.1016/j.bone.
2007.01.007
Yamada, C., Yamada, Y., Tsukiyama,
K., Yamada, K., Udagawa, N., Taka-
hashi, N., et al. (2008). The murine
glucagon-like peptide-1 receptor is
essential for control of bone resorp-
tion. Endocrinology 149, 574–579.
doi:10.1210/en.2007-1292
Yamamoto, H., Lee, C. E., Marcus, J.
N., Williams, T. D., Overton, J. M.,
Lopez,M. E., et al. (2002). Glucagon-
like peptide-1 receptor stimulation
increases blood pressure and heart
rate and activates autonomic regu-
latory neurons. J. Clin. Invest. 110,
43–52. doi:10.1172/JCI0215595
Zhong, Q., Itokawa, T., Sridhar,
S., Ding, K. H., Xie, D., Kang,
B., et al. (2007). Effects of
glucose-dependent insulinotropic
peptide on osteoclast function. Am.
J. Physiol. Endocrinol. Metab. 292,
E543–E548. doi:10.1152/ajpendo.
00364.2006
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 19 March 2013; accepted: 03
June 2013; published online: 18 June
2013.
Citation: Ceccarelli E, Guarino EG,Mer-
lotti D, Patti A, Gennari L, Nuti R
and Dotta F (2013) Beyond glycemic
control in diabetes mellitus: effects of
incretin-based therapies on bone metab-
olism. Front. Endocrinol. 4:73. doi:
10.3389/fendo.2013.00073
This article was submitted to Frontiers in
Bone Research, a specialty of Frontiers in
Endocrinology.
Copyright © 2013 Ceccarelli, Guarino,
Merlotti, Patti,Gennari,Nuti andDotta.
This is an open-access article distributed
under the terms of the Creative Com-
mons Attribution License, which per-
mits use, distribution and reproduction
in other forums, provided the original
authors and source are credited and sub-
ject to any copyright notices concerning
any third-party graphics etc.
Frontiers in Endocrinology | Bone Research June 2013 | Volume 4 | Article 73 | 12
